Prof. Jordan R. Hansford

Professor Jordan R. Hansford is a mid-career clinician specialising in the treatment of paediatric brain tumours. He is the lead in paediatric neuro-oncology at the Women’s and Children’s Hospital and lead of the Paediatric Neuro-Oncology Group at the South Australia Health and Medical Research Institute.

Professor Hansford is cross-appointed at the South Australia ImmunoGenomics Cancer Institute at the University of Adelaide. He is PI or co-PI on several national and international brain tumour studies including early phase studies and currently runs the paediatric brain cancer biobank in South Australia.

He has been awarded or co-awarded over $20M in funding for pre-clinical or clinical trials, is a director of ANZCHOG and the chair of their Neuro-Oncology group. He has led or contributed to many paediatric brain tumour trials leading to disease specific improvements to clinical care and outcomes in many disease types including practice changing targeted therapies in LGG.

In 2016 he was asked to participate in the international AACR cancer predisposition working group and in 2023 led their neuro-oncology group, leading to new guidelines for cancer surveillance for cancer predisposition.

Professor Hansford was invited to participate in the Australian Minister of Health’s National Roadmap to tackle Brain Cancer and the development of the Australian Brain Cancer Mission and previously sat on their board. Most recently, the ANZCHOG team has been focused on the translation of methylation Profiling to the upfront diagnostics of paediatric brain tumours that is now offered nationally as a NATA approved pathology test. This has led to changes in clinical practice across the country.